Back

Using dapagliflozin to reduce NT-proBNP and improve symptom in transthyretin cardiac amyloidosis - a series of n-of-1 trials pilot study

17 May 2025 (08:00 - 12:45)
Organised by: Logo
Congress Presentation Part of: ePosters in chronic heart failure - pharmacotherapy (2) Pharmacotherapy HFA Premium Access Heart Failure 2025 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Erik Haakansson

Umea University Hospital, Umea (Sweden)

5 More presentations in this session

Presentation thumbnail
Which treatment attributes do patients with transthyretin amyloid cardiomyopathy value most?
Ms A. Carr (Hagersville, CA)
Abstract Slides Video
Presentation thumbnail
Clinical characteristics and outcomes in a cohort of patients starting treatment with vericiguat in the US.
Doctor A. Michel (Basel, CH)
Abstract Slides Video
Presentation thumbnail
The care-gap for women living with heart failure
Doctor O. Graham (Craigavon, GB)
Abstract Slides Video
Presentation thumbnail
Intermittent levosimendan therapy and survival outcomes in advanced heart failure: insights from a real-world single-centre study
Doctor C. Gregorio (Lisbon, PT)
Abstract Slides Video
Presentation thumbnail
Ambulatory blood pressure monitoring reveals true significant hypotension in stable HF patients; Is this an overlooked issue?
Doctor G. Bruno (Limerick, IE)
Abstract Slides Video

Access the full session

Session thumbnail
ePosters in chronic heart failure - pharmacotherapy (2)

The Event

Event poster

Heart Failure 2025

17 May - 20 May 2025
You may be interested in
thumbnail
Congress Presentation
Sodium-glucose cotransporter 2 inhibitors for transthyretin amyloid cardiomyopathy: a systematic review and meta-analysis
thumbnail
Congress Presentation
Impact of sodium-glucose co-transporter inhibitors in mortality and decongestion in cardiac amyloidosis: A systematic review and meta-analysis
thumbnail
Congress Presentation
New horizons in transthyretin cardiac amyloidosis therapy: A systematic review and meta-analysis of sodium-glucose cotransporter 2 inhibitors efficacy

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources